Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.44 |
| ▸ | ADK | P55263 | 2/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | ADA | P00813 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319713 | 0.91 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL14598182 | 0.91 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL14453221 | 0.91 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL14453126 | 0.91 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL14598183 | 0.89 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL4425442 | 0.89 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL5320000 | 0.89 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL13598690 | 0.87 | ADORA3 (0.49) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL14453150 | 0.83 | ADORA2A (0.50) | ADORA2AADORA3ADORA1ADORA2BADK | |
| SCHEMBL14523035 | 0.82 | ADORA2A (0.60) | ADORA2AADORA3ADORA1ADORA2BADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADORA3 262/4885ADORA1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.